文献速递心力衰竭与心肌病血脂与心血管预防

SGLT2抑制剂心血管结局试验中心衰终点的评价:临床与监管问题

Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.
PubMed 文献 · Circulation · 2019-12-16

2008年FDA指南要求2型糖尿病新药的心血管结局试验以主要不良心血管事件为主要终点,心衰未被纳入重点,因此心衰结局并非预设主要终点。多项试验事后显示SGLT2抑制剂一致且显著降低心衰住院风险,但尚未获得心衰适应症批准或美国心衰指南推荐。2019年3月6日各方在FDA讨论非主要终点的说服力能否支持监管声明和指南推荐。

要点

  • SGLT2抑制剂在4项试验中一致且显著降低心衰住院风险
  • 心衰住院非预设主要终点,尚未获心衰适应症批准或指南推荐
  • 非主要终点的显著疗效能否支持监管声明和指南推荐仍需探讨

核心结论

  • SGLT2抑制剂在4项试验中一致且显著降低心衰住院风险,但尚未转化为心衰适应症批准或美国心衰指南推荐。
  • 需探讨非主要终点的显著疗效在多大程度上可支持监管声明和指南推荐。

研究设计与样本

  • 根据2008年FDA对2型糖尿病新药的监管指南,多项大型随机对照试验以主要不良心血管事件(心血管死亡、非致死性心肌梗死或非致死性卒中)为主要终点评估降糖药物安全性。
  • 心衰未被FDA指南特别提及,因此试验设计时未作为重点。
  • 2019年3月6日,研究人员、临床医生、企业申办方、监管机构和专业学会代表在FDA召开会议讨论相关议题。

主要发现

  • 多项试验事后显示降糖药物对心衰结局的影响,而心衰结局最初未指定为试验主要终点。
  • 最引人注目的发现是4项SGLT2抑制剂试验中一致且显著的心衰住院风险降低。
  • 这些结果尚未导致任何SGLT2抑制剂获得心衰适应症监管批准或美国心衰指南推荐。

临床怎么用

  • 临床医生应关注SGLT2抑制剂在2型糖尿病患者中降低心衰住院风险的证据。
  • 当前美国心衰指南尚未推荐SGLT2抑制剂用于心衰治疗,临床决策需结合监管现状。

局限性

  • 心衰结局并非试验预设主要终点,证据来自事后分析。
  • 非主要终点的治疗效应能否支持监管声明和指南推荐尚不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Following regulatory guidance set forth in 2008 by the US Food and Drug Administration for new drugs for type 2 diabetes mellitus, many large randomized, controlled trials have been conducted with the primary goal of assessing the safety of antihyperglycemic medications on the primary end point of major adverse cardiovascular events, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Heart failure (HF) was not specifically mentioned in the US Food and Drug Administration guidance and therefore it was not a focus of these studies when planned. Several trials subsequently showed the impact of antihyperglycemic drugs on HF outcomes, which were not originally specified as the primary end point of the trials. The most impressive finding has been the substantial and consistent risk reduction in HF hospitalization seen across 4 trials of sodium glucose cotransporter 2 inhibitors. However, to date, these results have not led to regulatory approval of any of these drugs for a HF indication or a recommendation for use by US HF guidelines. It is therefore important to explore to what extent persuasive treatment effects on nonprimary end points can be used to support regulatory claims and guideline recommendations. This topic was discussed by researchers, clinicians, industry sponsors, regulators, and representatives from professional societies, who convened on the US Food and Drug Administration campus on March 6, 2019. This report summarizes these discussions and the key takeaway messages from this meeting.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Butler J, Packer M, Greene SJ, et al. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. Circulation. 2019. PMID: 31841369. doi:10.1161/CIRCULATIONAHA.119.042155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。